Gink­go Bioworks hand­ed a DARPA man­u­fac­tur­ing con­tract; Mer­ck hits a pri­ma­ry end­point for Keytru­da in first-line cer­vi­cal can­cer

The De­fense Ad­vanced Re­search Projects Agency (DARPA) is giv­ing Gink­go Bioworks a 4-year con­tract worth up to $18 mil­lion, to man­u­fac­ture com­plex ther­a­peu­tic pro­teins.

Gink­go is part of DARPA’s “Reimag­in­ing Pro­tein Man­u­fac­tur­ing project,” which is de­signed to help the DOD get ac­cess to pro­teins more quick­ly. Gink­go plans to man­u­fac­ture pro­teins faster by us­ing its “cell-free pro­tein syn­the­sis to en­able rapid, high-yield” pro­duc­tion of pro­teins for na­tion­al se­cu­ri­ty ini­tia­tives.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.